EGFR and non-small cell lung carcinoma: In terms of safety, a pooled analysis of three cohorts of patients (N = 257) with NSCLC and EGFR ex20ins mutations receiving mobocertinib (160 mg/day) reported that the most common treatment‐related adverse events (AEs) were diarrhea (235 patients; 91%), followed by nausea (102 patients; 40%) and rash (94 patients; 37%) [16].